American Society of Hirudotherapy

Thyroid Eye Disease (Investigational Periocular Adjunct)

Highly investigational periocular adjunct for stable thyroid eye disease; ocular risk is critical; teprotumumab and orbital decompression remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for thyroid eye disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for thyroid eye disease was identified; a Russian medical book mentions, in a single sentence and without details, one case of an eye disease complicating autoimmune thyroiditis treated with leeches (see “What the books describe” below). Evidence-based first-line management is smoking cessation (critical), optimization of thyroid function, selenium supplementation in mild active disease, intravenous methylprednisolone for moderate-to-severe active disease, teprotumumab for active moderate-to-severe TED, orbital radiotherapy in select cases, and surgical orbital decompression for vision-threatening or quiescent severe disease.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Periocular bleeding, eyelid hematoma, or conjunctival bleeding (vision-threatening in active TED with proptosis)
  • Worsening of corneal exposure if eyelid swelling temporarily increases
  • Increased intraorbital pressure — theoretical risk to optic nerve in compressive TED
Who should not consider this
  • Patients with active vision-threatening TED (optic neuropathy, severe corneal exposure) — needs urgent IV steroids or surgery
  • Patients still smoking — smoking cessation alone often improves TED course substantially
  • Patients who have not had endocrine workup to confirm euthyroid status
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Have I had a full TED workup with an oculoplastic surgeon or endocrinologist?
  • Is my thyroid hormone level optimized and have I stopped smoking?
  • Am I a candidate for teprotumumab or IV methylprednisolone?
  • What is the published periocular leech-therapy safety record?
  • Who specifically will manage any bleeding or eyelid hematoma?
  • How will optic nerve function be monitored during the course?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Vision change of any kind — blurriness, color desaturation, dimness, or loss
  • Severe eye pain, especially with eye movement
  • Sudden inability to close the eye completely or new double vision

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for thyroid eye disease — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace teprotumumab, IV methylprednisolone, orbital decompression, or other proven TED treatments.
  • It does not change the underlying autoimmune process driving TED.
  • It does not address smoking, which is the single strongest modifiable TED risk factor.
  • No clinical study has been identified for this use, only a single case mentioned without details in a Russian medical book (see “What the books describe” below), and it carries periocular risks.

Clinical Profile

Category
Ophthalmologic
ICD-10
H06.2, E05.00
Safety tier
High

Evidence Summary

Thyroid eye disease (Graves orbitopathy) management follows EUGOGO 2021 guidelines: euthyroid status maintenance, smoking cessation, selenium for mild disease, teprotumumab (IGF-1R inhibitor, FDA-approved 2020) or intravenous methylprednisolone for moderate-severe active disease, and orbital decompression in the chronic stage. No clinical study of leech therapy for thyroid eye disease (of any design) was identified in PubMed, Europe PMC or ClinicalTrials.gov; the 2004 monograph by Baskova and Isakhanyan mentions only a single case of ophthalmopathy complicating autoimmune thyroiditis treated with leeches, without details (see “What the books describe” below); use is investigational and the rationale is mechanistic only. Any proposed local antiinflammatory or lymphatic-drainage rationale is theoretical and unsupported by clinical evidence, so the honest evidence grade is D. Leech application carries serious ocular-risk safety concerns, including corneal exposure and infection adjacency, and active TED is an absolute exclusion.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not discuss thyroid ophthalmopathy as a separate disease: in the section on eye diseases there is a single sentence saying that Vedeneeva and Medvedeva (2000) describe a case of “successful treatment with leeches of ophthalmopathy complicating the course of autoimmune thyroiditis”[B1].
  • This is the description of a single case; how the patient was treated and for how long the patient was observed is not stated in this sentence, and protrusion of the eyes (exophthalmos) in thyroid diseases is not discussed in the book[B1].
  • Among thyroid diseases, Baskova and Isakhanyan also give data on diffuse toxic goiter: in the work of Konstantinova and colleagues (1997) it was present in three of 22 patients, and their outcome is not named separately; in the work of Zhavoronkova (1998) leeches were combined with another procedure (phytoaeroionization), normalization of functional disturbances is described in all 40 patients with this goiter, but what part of the effect is due to the leeches is not clear from the text[B1].
  • Baskova and Isakhanyan write that in endocrinology leeches are most often used in diseases of the thyroid gland accompanied by reduced function of the gland, and name autoimmune thyroiditis and diffuse toxic goiter; how this fits with the name “toxic” goiter is not clear from the text[B1].
  • They attribute the effect in thyroid diseases to the anti-inflammatory and immunomodulatory action of hirudotherapy[B1].
  • Among the contraindications listed in the book by Baskova and Isakhanyan (their list is longer) are hemophilia, hemorrhagic diatheses, anemias and the simultaneous use of anticoagulants; Michalsen et al. (chapter 8, “Contraindications,” Flecken and Michalsen) call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active thyroid eye disease (CAS ≥3)
  • Optic neuropathy or vision-threatening disease
  • Corneal exposure or active keratitis
  • Uncontrolled hyperthyroidism
  • Recent teprotumumab or IV methylprednisolone (<3 months)
  • Any direct periocular placement

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.